The US Food and Drug Administration has approved a pre-exposure prophylaxis (PrEP) indication for Gilead Sciences’ (Nasdaq: GILD) Descovy (emtricitabine/tenofovir alafenamide).
The green light for the drug, as an option to reduce the risk of sexually acquired HIV-1 infection, comes seven years after Gilead won approval for Truvada (emtricitabine/tenofovir disoproxil fumarate) in this indication.
Descovy, which was approved as a treatment for HIV in 2016, took in $1.6 billion sales for Gilead in 2018, up from $1.2 billion in 2017, whereas Truvada generated $3 billion in revenue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze